Month: September 2026

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — With profound sadness, Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) announces the sudden passing of Stephen Scott on September 8, 2026. Mr. Scott served as President, CEO, and a director of the Company for over a decade until his retirement in July 2026.

Mr. Scott worked in the mining industry for more than 30 years, completing his education in Perth, Australia before joining Rio Tinto Exploration (RTX) Australasia. He worked for Rio Tinto for much of his career, including as President Director of Rio Tinto Indonesia, General Manager Commercial for Rio Tinto Canada, and Senior VP Corporate Development and Strategy for Turquoise Hill Resources. In 2014, having firmly established himself in Vancouver, British Columbia, Mr. Scott started a capital markets and management advisory consultancy. He joined Entrée in 2015 and successfully led the Company through restructuring and progressive steps to derisk the Company’s principal mining interest in Mongolia.      

Alan Edwards, Entrée’s Non-Executive Chair of the Board commented, “I had the fortunate privilege of working alongside Steve over the past ten years. He always approached the challenges of leadership with integrity and grace, while maintaining a wry Australian sense of humor. Steve was a wonderful colleague and an even better friend, and he will be greatly missed. On behalf of the Board and management at Entrée, we offer our sincere condolences to Steve’s family and many friends who cared so deeply about him.”

ABOUT ENTRÉE RESOURCES LTD.
Entrée Resources Ltd. is a Canadian mining company with a unique carried joint venture interest on a significant portion of one of the world’s largest copper-gold projects – the Oyu Tolgoi project in Mongolia. Entrée has a 20% or 30% carried participating interest in the Entrée/Oyu Tolgoi joint venture, depending on the depth of mineralization. Royal Gold (through its wholly owned subsidiary International Royalty Corporation) and Rio Tinto are major shareholders of Entrée, beneficially holding approximately 24% and 16% of the shares of the Company, respectively. More information about Entrée can be found at www.EntreeResourcesLtd.com.

FURTHER INFORMATION
David Jan
Investor Relations
Entrée Resources Ltd.
Tel: 604-687-4777 | Toll Free: 1-866-368-7330
E-mail: djan@EntreeResourcesLtd.com

This News Release contains forward-looking information within the meaning of applicable Canadian securities laws.

In certain cases, forward-looking information can be identified by words such as “plans”, “expects” or “does not expect”, “is expected”, “budgeted”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “does not anticipate” or “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will be taken”, “occur” or “be achieved”. While the Company has based this forward-looking information on its expectations about future events as at the date that such information was prepared, the information is not a guarantee of Entrée’s future performance and is based on certain assumptions.

Risks, uncertainties, and factors which could cause actual results, performance, or achievements of the Company to differ materially from future results, performance, or achievements expressed or implied by forward-looking information are discussed in the Company’s most recently filed MD&A and in the Company’s Annual Information Form for the financial year ended December 31, 2025, dated March 5, 2026 filed with the Canadian Securities Administrators and available at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company is under no obligation to update or alter any forward-looking information except as required under applicable securities laws.

Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today highlighted its participation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, held at the Bella Center Copenhagen.

Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA) System to interventional radiologists and healthcare professionals from around the world, providing an opportunity to engage with the global medical community and demonstrate the Company’s technology and approach to minimally invasive ablation.

Baird Medical’s MWA System is designed to deliver precise and controlled ablation and features temperature control technology, stable 2.45 GHz microwave energy delivery, and a range of specialized probes designed to support different clinical applications.

“Participating in CIRSE is an important part of Baird Medical’s continued engagement with the global medical community and reflects the international reach we have built across our business,” said Haimei Wu, Chairwoman and Chief Executive Officer of Baird Medical. “As we continue to strengthen our presence in the U.S. and across global markets, conferences like CIRSE provide valuable opportunities to connect with physicians from around the world, share our technology and deepen the relationships that support the broader adoption of minimally invasive treatment solutions.”

Baird Medical’s participation at CIRSE 2026 reflects the Company’s broader commitment to advancing minimally invasive treatment technologies and strengthening its engagement with physicians and healthcare institutions globally. As the Company continues to expand its presence internationally, most recently in Pakistan, Vietnam, and Argentina, Baird Medical remains focused on providing reliable, precise and versatile technologies designed to support physicians and improve treatment options for patients.

About Baird Medical

Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.

Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled “Risk Factors” therein, and in ExcelFin’s other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin’s most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7e99f8d1-7274-40cd-813c-fe0e717dc3ad

Five-year LOI contemplates purchase of up to 100% of commercially saleable copper and aluminum from Project Headwaters, representing more than $105 million of projected value at current commodity prices.

Agreement follows recently announced WMC Group lithium product offtake framework and further advances the commercial foundation for Aqua Metals’ planned domestic LFP recycling platform

RENO, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), a pioneer in sustainable lithium battery recycling, today announced that it has entered into a letter of intent (“LOI”) with a leading Midwest metals recycler for the purchase of recovered copper and aluminum expected to be produced at Project Headwaters, the Company’s planned commercial-scale lithium-ion battery recycling facility in the Midwestern United States.

Building upon the Company’s previously announced six-year lithium product offtake for the sale of lithium carbonate, Aqua Metals has now established offtake pathways for all three primary Project Headwaters product streams – lithium carbonate, copper and aluminum – in advance of construction.

Under the contemplated five-year agreement, the counterparty would purchase recovered copper and aluminum products from Project Headwaters, subject to product qualification and execution of a definitive agreement. Based on projected production volumes and current commodity prices, the copper and aluminum covered by the LOI represent more than $105 million of projected value over the contemplated five-year term.

The LOI provides a 24-month period to negotiate and execute a definitive offtake agreement. Final product specifications will be based on representative copper and aluminum produced by the Project Headwaters preprocessing system, with product qualification and execution of the definitive agreement expected as the initial phase of the facility begins producing material.

“We now have commercial pathways for every primary product stream at Headwaters, and we have them before we break ground,” said Steve Cotton, President and CEO of Aqua Metals. “Our objective is to build a recycling platform that can compete economically while recovering and keeping valuable battery materials within the domestic supply chain. Establishing commercial pathways for lithium, copper and aluminum materially advances that strategy.”

Copper and aluminum represent important sources of recoverable value from lithium-ion batteries and manufacturing scrap, particularly within the large-format lithium iron phosphate (“LFP”) battery streams Project Headwaters is being designed to process. Certain LFP batteries and manufacturing scrap can also carry processing or recycling fees, creating the potential for recyclers to generate revenue both when material enters the facility and through the sale of recovered products.

Project Headwaters is being designed to capture both sides of that economic opportunity. The planned preprocessing system will separate copper and aluminum from battery materials prior to downstream refining, producing distinct recyclable metal streams for sale into established domestic markets, while Aqua Metals’ proprietary AquaRefining™ technology is intended to recover lithium and other battery materials from the remaining feedstock.

Project Headwaters is being developed as an integrated domestic battery recycling facility combining battery preprocessing with AquaRefining technology. The planned facility is designed to recover and commercialize multiple material streams, including lithium carbonate, copper, aluminum, graphite and iron phosphate-containing materials, rather than relying on a single commodity for project economics.

Together, the lithium carbonate, copper and aluminum LOIs demonstrate Aqua Metals’ progress in establishing commercial outlets across multiple Project Headwaters product streams in advance of construction and commissioning. The Company believes these commercial relationships can help support project financing while reducing future commodity marketing and product-placement risk.

The contemplated copper and aluminum pricing would be tied to prevailing market benchmarks, subject to agreed product specifications and customary commercial terms. The LOI is non-binding and provides a framework for product qualification and negotiation of a definitive offtake agreement.

About Aqua Metals

Aqua Metals is advancing sustainable lithium battery recycling through its proprietary AquaRefining™ technology, an electro-hydrometallurgical process designed to recover critical battery materials using electricity rather than high-temperature processing. The Company is developing Project Headwaters as its first commercial-scale deployment focused on domestic recycling and refining of lithium-ion batteries and manufacturing scrap.

Forward-Looking Statements

This press release contains forward-looking statements, including statements concerning the proposed relationship with the counterparty; execution of a definitive offtake agreement; financing, development, construction, commissioning and operation of Project Headwaters; anticipated production volumes and product values; future commodity prices; product qualification; anticipated recovery and sale of copper and aluminum products; potential processing or recycling fees associated with LFP batteries and manufacturing scrap; the potential impact of U.S. policies supporting domestic critical-mineral processing and refining; and the expected commercial and economic benefits of the contemplated offtake arrangement.

Forward-looking statements are based on current expectations, estimates, assumptions and projections and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, (i) the risk that the Company may not enter into a definitive offtake agreement with the counterparty; (ii) even if it does, the Company’s ability to derive the expected benefits from such agreement; (iii) the Company’s ability to obtain the financing necessary to complete the development of its proposed Project Headwaters facility and otherwise secure long-term site control, negotiate and execute definitive agreements, and obtain permits and approvals concerning Project Headwaters; (iv) the risk that the Company may not be able to obtain the additional capital required to maintain its current level of operations; and (v) those additional risks described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026 and subsequent filings with the Securities and Exchange Commission. Aqua Metals undertakes no obligation to update forward-looking statements except as required by law.

Contacts

For Media and Investor Inquiries: aquametals@icrinc.com

FREMONT, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today announced its participation in AI Infra Summit 2026, from Sept. 15-17, 2026 at the Santa Clara Convention Center in California. Enphase will be at Booth 1454, showcasing its approach to next-generation AI data center power infrastructure, including the IQ^® Solid-State Transformer (IQ SST).

On Sept. 15 at 12:00 p.m. PDT, Raghu Belur, co-founder and chief product officer at Enphase Energy, will present “Solid-State Transformers: Speed to Power” on the AI Data Center Track.

The IQ SST is being developed to convert medium-voltage AC directly to 800 VDC for high-density AI data centers, with expected sub-millisecond response to dynamic AI loads. Its distributed architecture is designed to scale to racks up to 5 MW.

“AI data centers are forcing the industry to rethink how power moves from the grid to the rack,” said Raghu Belur. “At AI Infra Summit, we will show how Enphase is applying high-frequency magnetics, GaN power switching, custom silicon, and scalable domestic manufacturing to this challenge.”

Enphase recently began building IQ SST power modules at its manufacturing facility in Arlington, Texas, to assemble and validate full-scale IQ SST racks. A video of the power modules coming off the Enphase manufacturing line is available here.

Full-system demonstrations of IQ SST racks are expected in November 2026, with customer pilots planned for 2027. To learn more about IQ SST, visit the Enphase website.

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems, EV chargers, home energy management systems, and virtual power plant (VPP) solutions. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. The company revolutionized the solar industry with its microinverter-based technology and has shipped approximately 89.4 million microinverters, with approximately 5.3 million Enphase-based systems deployed in over 165 countries. For more information, visit https://enphase.com/.

©2026 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the expected development, validation, performance, product and technology capabilities, architecture, response times, manufacturing and scalability, supply chain, regulatory compliance, commercialization, and timing of full-system demonstrations and customer pilots for Enphase Energy’s IQ Solid-State Transformer (IQ SST). These forward-looking statements are based on Enphase Energy’s current expectations and assumptions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, Enphase Energy’s ability to develop, qualify, manufacture, validate, and commercialize the IQ SST and achieve the targeted technical and system-level performance, including direct conversion of medium-voltage AC to 800 VDC, anticipated sub-millisecond response to dynamic AI loads, and scalability to racks up to 5 MW; the ability to assemble and validate full-scale IQ SST racks and to scale U.S. production and achieve targeted output, yield, and cost; the ability to secure components and cost of supply, including gallium nitride (GaN); the ability of high-frequency magnetics, GaN power switching, custom silicon, and the distributed architecture to perform as intended; the pace and direction of the AI data center industry’s move toward 800 VDC and other changes in data center power architectures; customer adoption; the ability to satisfy applicable regulatory and policy requirements, including domestic content requirements; the timing of full-system demonstrations, customer pilots, and commercialization on the expected timeline; as well as competitive dynamics, execution risks related to entering new markets, and other factors discussed in Enphase Energy’s filings with the Securities and Exchange Commission, including those risks described in more detail in Enphase Energy’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, or changes in its expectations, except as required by law or otherwise.

Contact:

Enphase Energy
press@enphaseenergy.com

Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models. The findings establish a translational foundation for evaluating the compound in a naturally occurring disease setting while the company’s TNBC program simultaneously advances toward site initiation and Phase 1/2 patient enrollment.

Research Findings
Conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology) at Ohio State’s College of Veterinary Medicine, the study examined Telomir-Zn across three osteosarcoma cell line models: HOS (human), D17 (canine), and Abrams (canine). Researchers evaluated the dose-dependent anti-tumor activity of the compound across all three models.

All three osteosarcoma cell lines demonstrated growth inhibition at similar low drug concentrations. “Osteosarcoma in large-breed dogs remains devastating, with limited treatment options and poor outcomes,” noted Bracha, an associate professor at The Ohio State University College of Veterinary Medicine. “These findings suggest Telomir-Zn may offer a meaningful therapeutic opportunity for veterinary patients. The consistency of anti-tumor activity across both canine and human cell lines is particularly compelling because it positions us to explore efficacy in naturally occurring canine osteosarcoma—a model that could accelerate development for both animals and humans.”

These results validate the therapeutic potential of Telomir-Zn in osteosarcoma and support further translational investigation.

Osteosarcoma: An Unmet Clinical Need
Osteosarcoma is the most common primary bone malignancy in children and young adults. Despite decades of chemotherapy-based treatment, survival rates for metastatic disease remain below 30%, with minimal improvement over three decades. In veterinary medicine, osteosarcoma is similarly devastating in large-breed dogs, accounting for the majority of primary bone tumors.

The biological similarities between canine and human osteosarcoma, including genetics, tumor biology, and therapeutic response patterns, make the canine model one of the most clinically predictive disease models available for translational research.

Strategic Development Pathway
Based on these findings, Telomir is assessing osteosarcoma development in canine models as a potential therapeutic pathway, which could support both veterinary indication development and translational advancement toward human osteosarcoma:

• Track 1: TNBC in Humans — The company’s TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment under an active IND cleared by the FDA, targeting advanced or metastatic triple-negative breast cancer.
• Track 2: Osteosarcoma in Dogs — Based on these preclinical findings, Telomir is in conversations with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such research could accelerate clinical development in canine and human osteosarcoma.

While the company’s immediate focus remains advancing TNBC toward site initiation and Phase 1/2 patient enrollment, these preclinical findings position potential osteosarcoma development in canine models as a strategic opportunity. If pursued, such a dual-pathway approach could expand the therapeutic indication profile while advancing our platform.

The Iron-Modulation Platform
Telomir-Zn targets intracellular iron and copper homeostasis to modulate epigenetic pathways. The mechanism involves disruption of intracellular labile iron pools and inhibition of iron-dependent histone demethylases (KDMs), which reverses cancer-associated epigenetic silencing.

The company’s strategic focus is triple-negative breast cancer, where the TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment. The osteosarcoma preclinical findings provide an additional translational opportunity to validate the mechanism in a naturally occurring disease model (canine) while simultaneously advancing the lead TNBC indication.

Forward Outlook
Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals, said: “This research opens a strategic opportunity to develop Telomir-Zn across multiple oncology indications. Our TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment, and we are assessing next steps for potential osteosarcoma development. If successful with either indication, this multi-pronged approach could establish Telomir-Zn as a platform therapy targeting aggressive malignancies, meaningfully expanding our therapeutic scope.”

About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit https://telomirpharma.com/.

Telomir Pharmaceuticals Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words.

Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.

Telomir Pharmaceuticals Contact Information
Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

Clinical study to evaluate NS002, the Company’s investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional

Pivotal Study is planned for the fourth quarter of 2026; topline data readout anticipated first quarter 2027

TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE American: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. In addition to the current study approved in the IND, Nasus Pharma plans to initiate its pivotal study in the fourth quarter of 2026 and anticipates topline data readout from the study in the first quarter of 2027.

“FDA clearance of our IND for NS002 is a major development milestone for Nasus and represents a significant step toward the commercialization of this promising asset in a growing $2 billion market,” said Brendan O’Grady, Chief Executive Officer of Nasus Pharma. “Patients living with severe allergies today rely almost exclusively on needle-based autoinjectors. Based on the results from our recent Phase 2 study, which showed NS002 achieving the critical 100 pg/mL plasma epinephrine threshold with a median T100 of 1.69 minutes versus 3.47 minutes for EpiPen®, we believe NS002 presents an opportunity to address a significant unmet medical need for these patients. In a market currently dominated by injectables, NS002’s rapid onset and intranasal administration offer patients and caregivers a potentially superior alternative for treating severe allergic reactions. FDA clearance of our IND application brings us one step closer to offering that alternative to the millions of people at risk of anaphylaxis.”

About Nasus Pharma

Nasus Pharma Ltd. (NYSE American: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company’s lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus Pharma is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: the planned initiation of its pivotal clinical study for NS002 in the fourth quarter of 2026; the anticipation of topline data readout to be in the first quarter of 2027; the growing market for anaphylaxis treatment; and that FDA clearance of the Company’s IND application brings it one step closer to offering a needle-free alternative to millions of people at risk of anaphylaxis. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict, including the risk that the FDA may require additional information or studies before or after the pivotal study, that the pivotal study may not begin or conclude on the timeline the Company currently expects, and that results of the pivotal study may not support further development or approval of NS002. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions.  These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 25, 2026, and other documents filed with or furnished to the SEC which are available on the SEC’s website, www.sec.gov. Forward-looking statements contained in this press release are made as of this date and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact

Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact

Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

Lonquist to lead survey planning and data acquisition, building on recent technical work at Robinsons River

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has engaged Lonquist Field Service (Canada), ULC (“Lonquist”) to manage a targeted ground gravity survey at its 100%-owned Robinsons River Salt Project (the “Project”) in Newfoundland and Labrador. The engagement advances the ground gravity program announced by the Company on September 3, 2026.

Lonquist will coordinate survey planning and oversee third-party gravity data acquisition and processing. The program will build on the recent technical study, with additional measurements intended to fill gaps in existing gravity coverage across selected priority areas. The resulting data will complement the Project’s existing geological, drilling and geophysical information, supporting further evaluation of the subsurface interpretation and potential exploration targets.

“We are pleased to have Lonquist lead this next step at Robinsons River,” said Paul Sparkes, Chief Executive Officer of Vortex. “Their team’s recent technical work has helped identify where additional information would be most useful. This survey will allow us to build on that work and continue advancing our understanding of the Project.”

The survey design, contractor arrangements and schedule are being finalized. Fieldwork remains subject to the Company’s approval of the final program and confirmation of required permits and access arrangements. Vortex will provide further details as planning progresses. Gravity interpretations are non-unique and, on their own, cannot establish salt composition, thickness or continuity.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jared Suchan, Ph.D., P.Geo., Vice President of Exploration of the Company and a “Qualified Person” as defined by National Instrument 43-101.

For additional information concerning the Project and the Company’s data-verification and quality-assurance procedures, readers are referred to the Company’s technical report entitled Independent Technical Report on the Robinsons River Salt Property, dated July 31, 2023, available under the Company’s profile on SEDAR+.

About Vortex Energy Corp.

Vortex Energy Corp. is an exploration stage company engaged principally in the acquisition, exploration, and development of mineral properties in North America. The Company is currently advancing its Robinson River Salt Project comprised of a total of 942 claims covering 23,500 hectares located approximately 35 kilometres south of the town of Stephenville in the Province of Newfoundland & Labrador. The Robinson River Salt Project is prospective for both salt and hydrogen salt cavern storage. The Company is also currently advancing its Fire Eye Uranium Property in the Athabasca Basin, a region renowned for its uranium deposits.

On Behalf of the Board of Directors

Paul Sparkes

Chief Executive Officer, Director

+1 (778) 819-0164

info@vortexenergycorp.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current beliefs or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the Company’s exploration plans at the Project.

Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including, in respect of the forward-looking information included in this press release, assumptions regarding the Company’s ability to execute on its exploration plans, including that it will be successful in carrying out the planned drilling and that such drilling will yield the expected information and the desired outcomes.

Although forward-looking information is based on the reasonable assumptions of the Company’s management, there can be no assurance that any forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among other things, the risk that exploration at the Project does not proceed in the manner and on the timeline currently contemplated, or at all; risks inherent in the exploration and development of mineral deposits, including risks relating to receiving requisite permits and approvals, changes in project parameters or delays as plans continue to be redefined, that mineral exploration is inherently uncertain and that the results of mineral exploration may not be indicative of the actual geology or mineralization of a project; and that mineral exploration may be unsuccessful or fail to achieve the results anticipated by the Company, including as a result of factors beyond the Company’s control, such as geological conditions. The forward-looking information contained in this release is made as of the date hereof, and the Company not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.

MELBOURNE, Australia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Braiin Limited (NASDAQ:BRAI) (“Braiin” or the “Company”), a global AI platform company delivering automation and predictive analytics across precision agriculture, customer experience and property technology, announces that Braiin Limited Chief Executive Officer Natraj Balasubramanian will present a corporate overview in person at the H.C. Wainwright 28^th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

Presentation Date: September 15, 2026

Time: 1:00 PM ET (Fifth Floor)

Mr. Balasubramanian will be available for one-on-one meetings. To request a meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/

About Braiin Limited

Braiin Limited (NASDAQ:BRAI) is a global technology platform operating across AI, agritech, customer experience solutions, PropTech, and living infrastructure. Braiin’s ecosystem combines embedded distribution, intelligent automation, and recurring revenue platforms designed to support the lifecycle of the home and connected consumer services.

Cautionary Note Regarding Forward-Looking Statements.

This press release contains “forward-looking statements” within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included herein, including but not limited to such things as future business strategy, plans, and goals, and the expansion and growth of our business. The words “estimate”, “plan”, “anticipate”, “expect”, “intend”, “believe” “target”, “budget”, “may”, “can”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to” and similar words or expressions, or negatives of these terms or other variations of these terms or comparable language or any discussion of strategy or intention identify forward-looking statements. Please see the risk factors included in the Company’s United States Securities and Exchange Commission filings, which could cause actual results and events to differ materially from those contained in the forward-looking statements. You are cautioned against attributing undue certainty to forward-looking statements. Although these forward-looking statements were based on assumptions that the Company believes are reasonable when made, you are cautioned that forward-looking statements are not guarantees of future performance and that actual results, performance, or achievements may differ materially from those made in or suggested by the forward-looking statements in this press release. Any forward-looking statements made in this press release speak only as of the date of those statements. We undertake no obligation to update those statements or publicly announce the results of any revisions to any of those statements to reflect future events or developments.

Investor Relations Contact
Mike Mason
CORE IR
(212) 655-0924
ir@braiin.com

Public Relations Contact
Matthew Cossel
Core PR
(212) 655-0924
pr@braiin.com

WILMINGTON, N.C., Sept. 14, 2026 (GLOBE NEWSWIRE) — Live Oak Bank has been named the Official Business Bank of UNCW Athletics under a multi-year agreement, expanding a relationship that already includes title sponsorship of the Live Oak Bank Holiday Classic men’s basketball tournament.

The agreement gives Live Oak year-round presence across Seahawk athletics, including men’s and women’s basketball at Trask Coliseum and baseball at Brooks Field.

UNCW has been a talent pipeline for Live Oak for years, with more than 200 alumni employed at the bank. The bank is a consistent participant in Business Week at the Cameron School of Business, and its employees regularly mentor and volunteer across the university.

“Live Oak is Wilmington’s hometown bank, and UNCW is a significant part of what makes this city a place where businesses can thrive,” said William C. (BJ) Losch III, president of Live Oak. “More than 200 of our employees are UNCW graduates. Supporting Seahawk athletics is a direct investment in the university and the business community that has shaped our company.”

“Bringing together two institutions that are so deeply connected to Wilmington makes this partnership especially meaningful,” said UNCW Director of Athletics Michael Oblinger. “Live Oak Bank has been an incredible member of our community, and we are excited to build on our relationship and take it to the next level. Their commitment to UNCW and belief in the vision of Seahawk athletics reflects the shared values that make Wilmington such a special place to live, work and grow. We are grateful for their continued support and excited about the opportunities ahead as we work together to create an even greater impact for our student-athletes, our university and the greater Wilmington community.”

The sponsorship also gives Live Oak a platform to reach Wilmington’s small business owners. The bank’s mission is to serve America’s small businesses, and its products include business loans, along with business checking and savings accounts. Live Oak also offers high-yield personal savings and CD accounts for savers in Wilmington and across the country.

About Live Oak Bank

Live Oak Bank, a subsidiary of Live Oak Bancshares, Inc. (NYSE: LOB), is a digitally focused, FDIC-insured bank serving customers across the country. Live Oak brings efficiency and excellence to the banking process, without branches, by using a focused approach to technology and innovation. To learn more, visit liveoak.bank.

About the University of North Carolina Wilmington

UNC Wilmington, the state’s coastal university, is dedicated to the integration of teaching and mentoring with research and service. The university serves about 20,000 students and offers a full range of undergraduate and graduate-level programs, as well as select doctoral programs that address state needs. Learn more at uncw.edu.

Contact:
Madison Carlos
Live Oak Bank, Corporate Communications
910.386.6616
media.relations@liveoak.bank

• Up to $20 million two-tranche PIPE investment structure designed to accelerate AI-enabled wellness infrastructure.
• Parties plan to jointly pursue strategic acquisition of an AI hardware manufacturing enterprise valued between $20 million and $50 million.

Tokyo, JAPAN and New York, NY, Sept. 14, 2026 (GLOBE NEWSWIRE) — Linkage Global Inc. (NASDAQ: UZX) (“Linkage Global” or the “Company”), a technology-driven enterprise focused on AI-enabled wellness infrastructure, today announced that it entered into a non-binding Term Sheet (the “LOI”) for a strategic equity investment with Capital Finance Limited, a Hong Kong-based professional investment institution (“Capital Finance” or the “Investor”). Under the terms of the LOI, as amended by an addendum thereto (the “Addendum”)，Capital Finance proposes to make a total equity investment of up to US$20,000,000 through a two-tranche Private Investment in Public Equity (PIPE) structure in newly issued Class A ordinary shares of the Company.

The first tranche of $5,000,000 will be structured as a direct PIPE investment in newly issued Class A ordinary shares. The subscription price will be set at US$3.00 per share or 105% of the closing price of the Class A ordinary shares on the trading day immediately prior to closing, whichever is higher. At a baseline price of $3.00 per share, the first tranche represents approximately 1,666,667 Class A ordinary shares. The earliest target closing date for the first tranche is September 30, 2026. The first tranche will be governed by a definitive Securities Purchase Agreement to be executed within 10 business days after the execution of the LOI.

Within 30 business days following the closing of the first tranche, the Company and Capital Finance plan to jointly identify and evaluate an AI hardware manufacturing target company with an estimated enterprise valuation between $20 million and $50 million. Within 5 business days after the execution of an acquisition agreement with the target, Capital Finance will inject a second PIPE investment of up to $15,000,000. The subscription price for the second tranche will be the higher of (i) US$3.00 per share and (ii) 105% of the closing price of the Class A ordinary shares on the trading day immediately prior to the second tranche closing. The second tranche will be governed by a separate definitive Securities Purchase Agreement, the execution deadline of which will be determined separately by the parties.

“This proposed investment from Capital Finance Limited marks a significant endorsement of Linkage Global’s long-term vision, technology platform, and strategy to build an AI-enabled wellness ecosystem as next-generation healthcare infrastructure,” said Zhihua Wu, Chairman of Linkage Global. “As we continue to build out our AI-driven wellness infrastructure, securing strong capital partners enables us to accelerate innovation, expand our operational footprint, and build long-term value for our shareholders.”

Key Terms of the Proposed Investment

• Target Investment: Up to US$20,000,000.
• Transaction Structure: Exclusively Class A ordinary share PIPE issuances; for the avoidance of doubt, the entire transaction will not include any warrants, convertible notes, stock options, RSUs, other convertible securities or anti-dilution adjustments, any of which could result in further dilution
• Proposed Price: First tranche floor price of $3.00 per share (or 105% of market price if higher); Second tranche floor price of $3.00 per share (or 105% of market price if higher)
• The aggregate number of Class A ordinary shares issued to the Investor in the first tranche and to be issued to the Investor in the second tranche shall not exceed 49% of the Company’s then issued and outstanding Class A ordinary shares at the time of issuance of the second tranche Class A ordinary shares to the Investor.
• Due Diligence Period: A 60-day due diligence period accompanied by customary exclusivity covenants.

The LOI serves as a preliminary statement of commercial intent. Except for certain standard provisions, the terms are non-binding, and there can be no assurance that any definitive agreement will be reached or that the proposed transaction will be completed on the terms described or at all.

About Linkage Global Inc.

Linkage Global Inc. (NASDAQ: UZX) is a technology-driven enterprise pioneering global AI-enabled wellness infrastructure. Through its proprietary Human Resonance OS, the Company integrates self-developed neural acoustic algorithms, a portfolio of original wellness audio copyrights, and next-generation smart wearables to deliver data-driven, proactive wellness solutions to B2B and B2C markets worldwide. Founded on March 24, 2022, Linkage Global is headquartered in Tokyo, Japan. For more information, visit: https://linkagecc.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s plans, strategies and business development initiatives. There can be no assurance that any strategic initiative, partnership, offering launch, or other business plan described herein will be successfully executed or completed. This press release does not constitute guidance and should not be relied upon as indicative of future financial performance. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

Linkage Global Inc.
Investor Relations
Email: ir@linkagecc.com